851 related articles for article (PubMed ID: 16242776)
41. The induction of apoptosis by a combined 1,25(OH)2D3 analog, EB1089 and TGF-beta1 in NCI-H929 multiple myeloma cells.
Park WH; Seol JG; Kim ES; Binderup L; Koeffler HP; Kim BK; Lee YY
Int J Oncol; 2002 Mar; 20(3):533-42. PubMed ID: 11836565
[TBL] [Abstract][Full Text] [Related]
42. Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.
Kandasamy K; Srinivasula SM; Alnemri ES; Thompson CB; Korsmeyer SJ; Bryant JL; Srivastava RK
Cancer Res; 2003 Apr; 63(7):1712-21. PubMed ID: 12670926
[TBL] [Abstract][Full Text] [Related]
43. TGF-beta1 inhibition of apoptosis through the transcriptional up-regulation of Bcl-X(L) in human monocytic leukemia U937 cells.
Lee J; Park BJ; Park JH; Yang MH; Chi SG
Exp Mol Med; 1999 Sep; 31(3):126-33. PubMed ID: 10551260
[TBL] [Abstract][Full Text] [Related]
44. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria.
Zhang XD; Borrow JM; Zhang XY; Nguyen T; Hersey P
Oncogene; 2003 May; 22(19):2869-81. PubMed ID: 12771938
[TBL] [Abstract][Full Text] [Related]
45. Transforming growth factor-beta1 transcriptionally activates CD34 and prevents induced differentiation of TF-1 cells in the absence of any cell-cycle effects.
Marone M; Scambia G; Bonanno G; Rutella S; de Ritis D; Guidi F; Leone G; Pierelli L
Leukemia; 2002 Jan; 16(1):94-105. PubMed ID: 11840268
[TBL] [Abstract][Full Text] [Related]
46. Intracellular mechanisms mediating tocotrienol-induced apoptosis in neoplastic mammary epithelial cells.
Sylvester PW; Shah S
Asia Pac J Clin Nutr; 2005; 14(4):366-73. PubMed ID: 16326643
[TBL] [Abstract][Full Text] [Related]
47. Cooperative cytotoxicity of proteasome inhibitors and tumor necrosis factor-related apoptosis-inducing ligand in chemoresistant Bcl-2-overexpressing cells.
Nencioni A; Wille L; Dal Bello G; Boy D; Cirmena G; Wesselborg S; Belka C; Brossart P; Patrone F; Ballestrero A
Clin Cancer Res; 2005 Jun; 11(11):4259-65. PubMed ID: 15930365
[TBL] [Abstract][Full Text] [Related]
48. Molecular mechanisms underlying interferon-alpha-induced G0/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins.
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Oncogene; 1999 May; 18(18):2798-810. PubMed ID: 10362250
[TBL] [Abstract][Full Text] [Related]
49. Defining characteristics of Types I and II apoptotic cells in response to TRAIL.
Ozören N; El-Deiry WS
Neoplasia; 2002; 4(6):551-7. PubMed ID: 12407450
[TBL] [Abstract][Full Text] [Related]
50. Failure of Bcl-2 to block mitochondrial dysfunction during TRAIL-induced apoptosis. Tumor necrosis-related apoptosis-inducing ligand.
Kim EJ; Suliman A; Lam A; Srivastava RK
Int J Oncol; 2001 Jan; 18(1):187-94. PubMed ID: 11115558
[TBL] [Abstract][Full Text] [Related]
51. NF-kappa B does not modulate sensitivity of renal carcinoma cells to TNF alpha-related apoptosis-inducing ligand (TRAIL).
Pawlowski JE; Nesterov A; Scheinman RI; Johnson TR; Kraft AS
Anticancer Res; 2000; 20(6B):4243-55. PubMed ID: 11205254
[TBL] [Abstract][Full Text] [Related]
52. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP.
Kang J; Bu J; Hao Y; Chen F
Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917
[TBL] [Abstract][Full Text] [Related]
53. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
Zhang L; Fang B
Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
[TBL] [Abstract][Full Text] [Related]
54. Arsenic trioxide induces apoptosis in pancreatic cancer cells via changes in cell cycle, caspase activation, and GADD expression.
Li X; Ding X; Adrian TE
Pancreas; 2003 Aug; 27(2):174-9. PubMed ID: 12883267
[TBL] [Abstract][Full Text] [Related]
55. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.
Baader E; Toloczko A; Fuchs U; Schmid I; Beltinger C; Ehrhardt H; Debatin KM; Jeremias I
Cancer Res; 2005 Sep; 65(17):7888-95. PubMed ID: 16140959
[TBL] [Abstract][Full Text] [Related]
56. TRAIL-induced apoptosis in human vascular endothelium is regulated by phosphatidylinositol 3-kinase/Akt through the short form of cellular FLIP and Bcl-2.
Alladina SJ; Song JH; Davidge ST; Hao C; Easton AS
J Vasc Res; 2005; 42(4):337-47. PubMed ID: 15985761
[TBL] [Abstract][Full Text] [Related]
57. Triptolide sensitizes resistant cholangiocarcinoma cells to TRAIL-induced apoptosis.
Panichakul T; Intachote P; Wongkajorsilp A; Sripa B; Sirisinha S
Anticancer Res; 2006; 26(1A):259-65. PubMed ID: 16475706
[TBL] [Abstract][Full Text] [Related]
58. Activation of caspase-8 in transforming growth factor-beta-induced apoptosis of human hepatoma cells.
Shima Y; Nakao K; Nakashima T; Kawakami A; Nakata K; Hamasaki K; Kato Y; Eguchi K; Ishii N
Hepatology; 1999 Nov; 30(5):1215-22. PubMed ID: 10534343
[TBL] [Abstract][Full Text] [Related]
59. Protein kinase C activation modulates pro- and anti-apoptotic signaling pathways.
Meinhardt G; Roth J; Totok G
Eur J Cell Biol; 2000 Nov; 79(11):824-33. PubMed ID: 11139146
[TBL] [Abstract][Full Text] [Related]
60. A small-molecule c-Myc inhibitor, 10058-F4, induces cell-cycle arrest, apoptosis, and myeloid differentiation of human acute myeloid leukemia.
Huang MJ; Cheng YC; Liu CR; Lin S; Liu HE
Exp Hematol; 2006 Nov; 34(11):1480-9. PubMed ID: 17046567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]